CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −24,449 | $35.57 | $870K | 4,523,951 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −28,718 | $36.40 | $1.0M | 4,495,233 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −41,763 | $37.41 | $1.6M | 4,453,470 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −183,868 | $38.48 | $7.1M | 4,269,602 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −96,386 | $39.26 | $3.8M | 4,173,216 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −5,133 | $35.57 | $183K | 796,889 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −6,030 | $36.40 | $219K | 790,859 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −8,769 | $37.41 | $328K | 782,090 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −38,606 | $38.48 | $1.5M | 743,484 |
| 2024-07-09 | Booth Bruce Director | Sale 10b5-1 | −20,238 | $39.26 | $795K | 723,246 |
| 2024-07-01 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +18,773 | $5.33 | $100K | 649,959 |
| 2024-07-01 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −18,773 | 288,456 | ||
| 2024-06-27 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion | +25,000 | $2.08 | $52K | 168,554 |
| 2024-06-27 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −25,000 | 104,899 | ||
| 2024-06-18 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Ridloff Elena Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Hrustanovic Gorjan Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | MARAGANORE JOHN Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 |
Page 26 of 41 · 810 trades